CIM
IBB icon

Contravisory Investment Management’s iShares Biotechnology ETF IBB Stock Holding History

Contravisory Investment Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-78
Closed -$8K – 386
2017
Q4 		$8K Buy
+78
New +$8.34K ﹤0.01% 274
2014
Q4 		– Sell
-300
Closed -$27K – 168
2014
Q3 		$27K Hold
300
– – 0.01% 92
2014
Q2 		$26K Buy
+300
New +$23.6K 0.01% 95

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
N
Natixis Paris, France $24.8B AUM 35.22% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Contravisory Investment Management's IBB Position: Q1 2018 in Review

Contravisory Investment Management sold out of iShares Biotechnology ETF (IBB) in Q1 2018, closing a stake of 78 shares — an estimated $8K sold.

Contravisory Investment Management first reported a position in IBB in Q2 2014 and held it in 3 quarters. The position peaked at $27K in Q3 2014. 607 funds tracked by Wall St. Rank hold IBB as of Q1 2018.

  • Contravisory Investment Management reported no remaining iShares Biotechnology ETF position as of Q1 2018 after selling out during the quarter.
  • Contravisory Investment Management sold 78 iShares Biotechnology ETF shares in Q1 2018, an estimated $8K.
  • Contravisory Investment Management first reported a position in iShares Biotechnology ETF in Q2 2014 and held it in 3 quarters.
  • Contravisory Investment Management's iShares Biotechnology ETF position peaked at $27K in Q3 2014.
  • 607 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2018.

Based on Contravisory Investment Management's 13F filing for Q1 2018, filed 9 Apr 2018.